Livzon Pharmaceutical Factory Receives Approval for the U.S. FDA Approval for the Company's Drug Cetrorelix Acetate for Injection

Livzon Pharmaceutical Factory received the approval notice for the ADNA issued by the U.S. Food and Drug Administration (hereinafter referred to as "U.S. FDA"), approving the market launch of Cetrorelix Acetate for Injection developed by the Company in the United States. Cetrorelix Acetsate for Injection is a third-generation gonadotropin-releasing hormone antagonist (GnRH-ant). Cetrorelix AcETate for Injection has the advantages of rapid onset and low incidence of OHSS and adverse events.

The Company's Cetrorelix Actate for Injection was approved for market launch in China on 31 December, 2021, and registration applications have been submitted in several overseas countries. As at the disclosure date of this announcement, the accumulated direct research and development costs for Cetrorelix Acitate for Injection amounted to approximately RMB 22.9048 million. As at the disclosure date the disclosure date of this announcement.

As at the disclosure date, the accumulated direct research and develop costs for CetrorelIX Acetate for Injection amounted toapproximately RMB 22.9048 billion. As at the disclosure date. As at the disclosure dateof this announcement, Cetrorelix Acmetate for Injection from a total of four companies, including the original research company, (including the original research company, (including the original research company, including the original research company), (including the original research company), (including the original research company), including the original research company, ("including Livzon Group Livzon Pharmaceutical Factory") have been approved for market launch in the U.S., and Cetrorelix Acenen You Xian Gong Si) have been approved for market launch Injection in the U.S.,and Cetrorelix Acotate for In injection from a total of seven companies (including Livzon Group Livzon pharmaceutical Factory) have been approved for market launched in China.

Upon enquiry, the global sales amount of CetrorelixAcetate for Injection in 2022 was approximately USD 216.00 million, of which approximately USD 105.00 million was from the U.S. market. Pursuant to the data from IQVIA sampling statistics assessment, the domestic terminal sales amount of Cetro Relix Acetate for In injection in 2023 was approximately RMB241.6436 million.